Page last updated: 2024-09-04

resiquimod and Infections, Chlamydia

resiquimod has been researched along with Infections, Chlamydia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Cocco, MJ; de la Maza, LM; le Bon, C; Pal, S; Tifrea, DF; Zoonens, M1
Aldon, Y; Blakney, AK; Christensen, D; Follmann, F; McKay, PF; Shattock, RJ; Yus, BI1

Other Studies

2 other study(ies) available for resiquimod and Infections, Chlamydia

ArticleYear
Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant.
    Vaccine, 2020, 06-09, Volume: 38, Issue:28

    Topics: Adjuvants, Immunologic; Animals; Antibodies, Bacterial; Bacterial Outer Membrane Proteins; Bacterial Vaccines; Chlamydia Infections; Chlamydia muridarum; Imidazoles; Mice; Mice, Inbred BALB C; Oligodeoxyribonucleotides

2020
Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA.
    Journal of controlled release : official journal of the Controlled Release Society, 2019, 06-28, Volume: 304

    Topics: Adjuvants, Immunologic; Animals; Bacterial Vaccines; Cations; Chlamydia Infections; Chlamydia trachomatis; Female; Heterocyclic Compounds, 3-Ring; Imidazoles; Immunity, Cellular; Immunity, Humoral; Immunogenicity, Vaccine; Immunologic Factors; Liposomes; Mice; Mice, Inbred BALB C; RNA; Stearic Acids; Transfection

2019